MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with E

Entacapone

Entacapone 200mg tablets

Use with caution

Stability notes for Entacapone 200mg tablets

Protect from light.

Provenance

This compatibility recommendation is derived from Comtess 200mg tablets (Orion Pharma (UK) Ltd).

Suppliers (7) of Entacapone 200mg tablets
Entacapone 200mg tablets (A A H Pharmaceuticals Ltd)
Entacapone 200mg tablets (Alliance Healthcare (Distribution) Ltd)
Entacapone 200mg tablets (HEC Pharm GmbH)
Entacapone 200mg tablets (Medihealth (Northern) Ltd)
Entacapone 200mg tablets (Sigma Pharmaceuticals Plc)
Entacapone 200mg tablets (Teva UK Ltd)
Entacapone 200mg tablets (Viatris UK Healthcare Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.